Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial-Reference-Cited by-同舟云学术

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial

Published:2022-10 Issue:10358 Volume:400 Page:1103-1116
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Pal Sumanta Kumar,Uzzo Robert,Karam Jose Antonio,Master Viraj A,Donskov Frede,Suarez Cristina,Albiges Laurence,Rini Brian,Tomita Yoshihiko,Kann Ariel Galapo,Procopio Giuseppe,Massari Francesco,Zibelman Matthew,Antonyan Igor,Huseni Mahrukh,Basu Debasmita,Ci Bo,Leung William,Khan Omara,Dubey Sarita,Bex Axel

Funder

F Hoffmann-La Roche Ltd

F. Hoffmann-La Roche

Genentech

Publisher

Elsevier BV

Subject

General Medicine

Reference27 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma;Lam;Urology,2005

3. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma;Powles;Ann Oncol,2021

4. European Association of Urology guidelines on renal cell carcinoma: the 2022 update;Ljungberg;Eur Urol,2022

5. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy;Ravaud;N Engl J Med,2016

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant treatment in renal cell carcinoma: a never-ending story?;The Lancet;2024-02

2. Novel Approaches with HIF-2α Targeted Therapies in Metastatic Renal Cell Carcinoma;Cancers;2024-01-31

3. Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival;Cancers;2024-01-28

4. Adjuvant Therapy in Renal Cell Cancer;Kidney Cancer;2024-01-22